SEC Form 4 · accession 0001567619-19-005839
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles N York II
Officer — Chief Financial Officer and VP
Period of report
Feb 28, 2019
Accepted (ET)
Mar 1, 2019 · 5:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $8.36 | Feb 28, 2019 | A | 87,600 | A | — | Feb 27, 2029 | Common Stock | 87,600 | 87,600 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 28, 2019, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.